Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection

Fertil Steril. 2009 Jun;91(6):2455-60. doi: 10.1016/j.fertnstert.2008.04.013. Epub 2008 Jun 13.

Abstract

Objective: To review 10 years of experience providing fertility care to men seropositive for human immunodeficiency virus (HIV) using sperm washing and in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI).

Design: Retrospective study.

Setting: University-based practice.

Patient(s): HIV-seropositive men with HIV-seronegative partners.

Intervention(s): IVF-ICSI, HIV testing of females and infants.

Main outcome measure(s): IVF performance, pregnancy rates, obstetrical outcomes, infection rates.

Result(s): We initiated 420 cycles (355 fresh and 65 frozen cycles) in 181 couples. Due to poor ovarian response, 16% of stimulations were canceled. The number of oocytes collected per retrieval was 15.0 +/- 0.5, providing 12.1 +/- 0.5 mature oocytes suitable for ICSI, yielding 9.0 +/- 0.3 embryos per couple. The overall clinical pregnancy rate/embryo transfer was 45%; ongoing/delivered pregnancy rate/embryo transfer was 37%. The most frequent obstetric complication was multiple gestation (41%), with 5% experiencing high order multiple birth. An attendant high rate of preterm delivery was noted, as 43% of infants were born premature. No maternal or neonatal HIV infections or deaths occurred.

Conclusion(s): We have found IVF-ICSI to be an expeditious and safe means for HIV-serodiscordant couples to achieve pregnancy with minimal risk of viral infection. Risks and liabilities of IVF-ICSI relate to multiple gestations and will occur in a significant number of participants.

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Female
  • Fertility / physiology*
  • Fertilization in Vitro / statistics & numerical data*
  • Freezing
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / physiopathology*
  • HIV Seropositivity / transmission
  • Hemophilia A / drug therapy
  • Hemophilia A / epidemiology
  • Hepatitis B / drug therapy
  • Hepatitis B / epidemiology
  • Hepatitis C / drug therapy
  • Hepatitis C / epidemiology
  • Humans
  • Infant, Newborn
  • Live Birth / epidemiology
  • Male
  • Middle Aged
  • Pregnancy
  • Retrospective Studies
  • Sperm Injections, Intracytoplasmic / statistics & numerical data*
  • Spermatozoa / physiology*
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents